<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">2815</id>
  <title>T3D2773</title>
  <common-name>Procyclidine</common-name>
  <description>Procyclidine is only found in individuals that have used or taken this drug. It is a muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. The mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation.</description>
  <cas>77-37-2</cas>
  <pubchem-id>4919</pubchem-id>
  <chemical-formula>C19H29NO</chemical-formula>
  <weight>287.224920</weight>
  <appearance>White powder.</appearance>
  <melting-point>86°C</melting-point>
  <boiling-point nil="true"/>
  <density nil="true"/>
  <solubility>Moderately soluble in water, ~ 30 mg/ml</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Oral</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity>The mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Procyclidine exerts an antispasmodic effect on smooth muscle, and may produce mydriasis and reduction in salivation.</mechanism-of-toxicity>
  <metabolism></metabolism>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt;=60 mg/kg (IV in mice)</toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>For the treatment of all forms of Parkinson's Disease, as well as control of extrapyramidal reactions induced by antipsychotic agents.</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms>LD&lt;sub&gt;50&lt;/sub&gt;=60 mg/kg (IV in mice)</symptoms>
  <treatment nil="true"/>
  <created-at type="dateTime">2009-07-21T20:26:46Z</created-at>
  <updated-at type="dateTime">2014-12-24T20:25:51Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Procyclidine</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id>C07378</kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>8448</chebi-id>
  <biocyc-id></biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id>Procyclidine</stitch-id>
  <drugbank-id>DB00387</drugbank-id>
  <pdb-id></pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>OC(CCN1CCCC1)(C1CCCCC1)C1=CC=CC=C1</moldb-smiles>
  <moldb-formula>C19H29NO</moldb-formula>
  <moldb-inchi>InChI=1/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2</moldb-inchi>
  <moldb-inchikey>InChIKey=WYDUSKDSKCASEF-UHFFFAOYNA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">287.4397</moldb-average-mass>
  <moldb-mono-mass type="decimal">287.224914555</moldb-mono-mass>
  <origin>Exogenous</origin>
  <state>Solid</state>
  <logp>4.2</logp>
  <hmdb-id>HMDB14531</hmdb-id>
  <chembl-id>CHEMBL86715</chembl-id>
  <chemspider-id>4750</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference></synthesis-reference>
  <structure-image-caption nil="true"/>
</compound>
